RxDoctor Payments Data

Valerie Shoichet

Medical · Brooklyn, NYNPI 1437451358

Payments from drug & device makers

$772in general payments, 2019–2025

Across 35 payments — averaging $22.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Urogen Pharma, Inc.$223
  • Hollister Incorporated$177
  • Medtronic$89
  • Novo Nordisk$59
  • AbbVie$50
  • Civco Medical Instruments$26
  • plus $148 from 8 others

What the payments were for

  • Food & beverage$772100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Urogen Pharma, Inc.9$223
Hollister Incorporated8$177
Medtronic4$89
Novo Nordisk3$59
AbbVie2$50
Civco Medical Instruments1$26
Astellas Pharma US Inc1$24
Immunitybio, Inc.1$22
Teleflex LLC1$21
Axonics, Inc.1$19
ABC Home Medical Supply, Inc.1$19
Clarus Therapeutics Inc.1$16
Dentsply IH Inc.1$14
Boston Scientific1$13

How this compares

$772 in reported general payments places this provider in the 60th percentile of 2,395 medical providers in New York.

See all medical providers in New York

Medicare billing

Part B allowed, 2024
$92,439
Medicare patients
597
Services billed
1,506

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron570$361,874
MyrbetriqMirabegron493$279,972
Estradiol360$26,724
EstringEstradiol33$18,105
Mirabegron ErMirabegron27$17,401
Fesoterodine Fumarate ErFesoterodine Fumarate123$9,957
Solifenacin Succinate134$6,806
PremarinEstrogens, Conjugated13$5,632
YuvafemEstradiol42$5,268
Trospium Chloride ErTrospium Chloride43$4,288
Tolterodine Tartrate ErTolterodine Tartrate55$2,744
Trospium Chloride73$2,656
Methenamine Hippurate40$2,503
Darifenacin ErDarifenacin Hydrobromide14$2,214
Clobetasol Propionate22$797

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$24$279,972493 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,395 medical providers in New York.

Other medical in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →